Why Is NRx Pharmaceuticals Stock Falling After Data From Suicidal Bipolar Depression Study - NRX Pharmaceuticals (NASDAQ:NRXP)
NRX Pharmaceuticals announces Phase 2b/3 trial findings of NRX-101 vs. Lurasidone for Suicidal Bipolar Depression.
Nrx Pharmaceuticals Inc Suicidal Bipolar Montgomery Asberg Depression Rating Scale Columbia Suicide Severity Rating Scale Black Box Special Protocol Agreement
Source: benzinga.com